Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Cheng

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Leukemia|May 7, 2025
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variantsRyan J Stubbins, Stephen Arnovitz, Jennie Vagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2023
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung CancerBruna Pellini, Russell W Madison, Merrida A Childress, et al.
Plos One|October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Plos One|January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Nature|April 1, 2026
Investigating the reproducibility of the social and behavioural sciencesOlivia Miske, Anna Lou Abatayo, Mason Daley, et al.
Nature|April 1, 2026
Investigating the replicability of the social and behavioural sciencesAndrew H Tyner, Anna Lou Abatayo, Mason Daley, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Leukemia|May 7, 2025
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variantsRyan J Stubbins, Stephen Arnovitz, Jennie Vagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2023
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung CancerBruna Pellini, Russell W Madison, Merrida A Childress, et al.
Plos One|October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Plos One|January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Nature|April 1, 2026
Investigating the reproducibility of the social and behavioural sciencesOlivia Miske, Anna Lou Abatayo, Mason Daley, et al.
Nature|April 1, 2026
Investigating the replicability of the social and behavioural sciencesAndrew H Tyner, Anna Lou Abatayo, Mason Daley, et al.
Pageof 9